Pharma Turkey Dergisi Eylül – Ekim 2017 Sayısı

The FDA-approved drug VENCLYXTO
(venetoclax) used in AbbVie’s chronic
lymphocytic leukemia (CLL) cancer received
a license in Turkey
VENCLYXTO is indicated in patients with chronic
lymphocytic leukemia who have been shown to have a 17p
deletion / TP53 mutation and BCL-2 positive for at least
3 months with ibrutinib or idelalisib, but at least partial
response is not available.
AbbVie has been licensed in Turkey for VENCLYXTO
(venetoclax), an FDA-approved drug used in
the treatment of chronic lymphocytic leukemia
(CLL) cancer. VENCLYXTO is indicated in
patients with chronic lymphocytic leukemia
who have been shown to have a 17p deletion /
TP53 mutation and BCL-2 positive for at least
3 months with ibrutinib or idelalisib in at least
partial response. VENCLYXTO is indicated in
patients with chronic lymphocytic leukemia who
have been shown to have 17p deletion / TP53
mutation negative and BCL-2 positive, but who
have at least 3 partial chemoimmunotherapy
treatments including ibrutinib or idelalisib
treatment, or who have at least partial response
or recurrence.
VENCLYXTO is evaluated for the treatment
of patients with various types of blood
cancers. Some cells, including BCL-2 protein
lymphocytes, inhibit apoptosis (programmed
cell death) and can be overexpressed in CLL
cells. Once a day, VENCLYXTO is designed to
selectively suppress the function of the BCL-2
protein.
AbbVie Turkey Medical Director Dr. Mahmut
Gucuk, said that offering VENCYLXTO to
medical service is an important step taken for
chronic lymphocytic leukemia patients in Turkey.
AbbVie pioneered in investigating ways to block
BCL-2 activity. As the first BCL-2 inhibitor
approved, VENCYLXTO also fulfills the promise
of developing cancer drugs in areas where
AbbVie has unmet needs.
Chronic lymphocytic leukemia (KLL), which is a
type of blood and bone marrow cancer, is usually
slow. A 17p deletion, a genomic alteration in
which a portion of chromosome 17 is absent,
occurs in 3 to 10 percent of previously treated
CLL cases; and 30 to 50 percent of relapsed
or refractory CLL cases. In primary care, 8
to 15 percent of patients are treated; and 35
to 50 percent of refractory CLL cases have a
TP53 mutation. The prognosis for patients with
17p deletion or TP53 mutations is generally
poor and the median life expectancy in current
standard treatment regimens is less than two
to three years. The average age for diagnosis of
KLL patients, one of the most common types of
leukemia, is 70 years. While approximately 3,500
people are caught in Turkey each year, the rate in
the world is accepted as 4.5 / 100,000.
VENCLYXTO has obtained license approval
in the USA, EU, Argentina, Puerto Rico and
Canada. VENCYLXTO is developed by AbbVie
and Genentech of the Roche Group. It is offered
by two companies in the US together with AbbVie
outside the United States.
Pharma
September- October ‘17 23